NEW YORK – QuidelOrtho this week launched a secondary public offering of its common stock on behalf of a selling stockholder, Carlyle Partners VI Cayman Holdings. The firm offered 8,260,183 shares of its common stock at $35.314 per share. QuidelOrtho will receive no proceeds from the sale. In connection with the sale, James Prutow and Robert Schmidt resigned from QuidelOrtho's board of directors on Nov. 21. The resignations were submitted in accordance with the principal stockholder's agreement dated Dec. 22, 2021, between QuidelOrtho and Carlyle.
Revvity said this week that its Omics laboratory in Manchester, UK, will extract DNA from cord blood samples collected from newborns across England for Genomics England's Generation Study, using Revvity's Chemagic 360 instrument. The study aims to screen up to 100,000 newborns for 200 rare genetic conditions by genomic testing. Revvity previously collaborated with Genomics England on various research projects at a smaller scale, according to a company spokesperson.
German genomic testing company CeGaT said this week that it has contracted with several health insurance programs and companies in the US. The firm, which has a US office in Chicago, is now in network with TriCare East, BCBS Nationwide, Medicare, and Medicaid programs in states including Illinois, Michigan, Ohio, Kansas, Colorado, Iowa, Idaho, and Georgia.
Mindera Health this week announced a partnership with patient advocacy organization National Psoriasis Foundation to raise awareness of personalized medicine within psoriasis and accelerate adoption of its transcriptomics test, Mind.Px. The test is designed to predict which class of biologic a patient is likely to respond to, based on an analysis of mRNA. The National Psoriasis Foundation provides patients with resources, tools, and educational information to manage psoriasis.
Fluxergy said this week that it will collaborate with the National Institute of Allergy and Infectious Diseases at the National Institutes of Health on the development of molecular testing and sample preparation capabilities that will be incorporated into the company's point-of-care tests for sexually transmitted infections and the causes of vaginosis. The firm said that it will work with the NIAID's Diagnostics Development Services program and NIAID-funded contractors to evaluate the compatibility of the Fluxergy Test Card with rapid nucleic acid extraction and purification methods. Fluxergy said that it intends to develop highly sensitive sample-to-answer molecular tests for Gram-negative bacteria and fungal pathogens that cause sexually transmitted infections and vaginosis.
Biotech firm NeuroKaire said this week that it has received Clinical Laboratory Improvement Amendments certification from the US Centers for Medicare and Medicaid Services to perform high-complexity clinical testing. The company said that its first offering is a pharmacogenetic assay for 95 variants in 24 genes to guide treatment with 132 drugs for various psychiatric and neurological conditions.
Agilent Technologies said this week that its board of directors has approved a quarterly dividend of $.25 per share of its common stock, payable on Jan. 22, 2025, to shareholders of record on Dec. 31.
Renalytix this week announced its Q1 results for fiscal year 2025, reporting revenues of $522,000, up from $459,000 in the year-ago quarter. Net loss was $4.7 million, or $.04 per share, down from a net loss of $10.2 million, or $.11 per share, in fiscal Q1 2024. Renalytix ended the quarter with $909,000 in cash and cash equivalents. The firm said it secured additional rounds of equity financing totaling £11.8m ($14.9 million) after the end of the quarter and believes it will be able to fund current operations for the next year. Renalytix also issued guidance on multiyear revenue generation, saying it expects revenues of approximately $3.2 million in fiscal year 2025, $8.5 million in fiscal year 2026, and $17.5 million in fiscal year 2027.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.